TScan Therapeutics(TCRX) - 2025 Q2 - Quarterly Results

Exhibit 99.1 TScan Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update Two-year relapse data from ALLOHA™ Phase 1 heme trial to be presented by end of year Expects to dose first solid tumor patients with multiplex TCR-T in the third quarter of 2025 Cash, cash equivalents, and marketable securities continue to fund operations into the first quarter of 2027 WALTHAM, Mass., Aug 12, 2025 -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focus ...